Long non‑coding RNA SUMO1P3 promotes tumour progression by regulating cell proliferation and invasion in glioma

Deng,Danni; Mo,Yi; Xue,Lian; Shao,Naiyuan; Cao,Jie

doi:10.3892/etm.2021.9922

Long non‑coding RNA SUMO1P3 promotes tumour progression by regulating cell proliferation and invasion in glioma

Authors:
- Danni Deng
- Yi Mo
- Lian Xue
- Naiyuan Shao
- Jie Cao
View Affiliations

Affiliations: Department of Neurosurgery, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213000, P.R. China, Department of Neurosurgery, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213000, P.R. China
Published online on: March 16, 2021 https://doi.org/10.3892/etm.2021.9922
Article Number: 491
Copyright: © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gliomas account for 50% of primary brain tumours in the central nervous system. Small ubiquitin‑like modifier 1 pseudogene 3 (SUMO1P3), a newly identified long non‑coding RNA (lncRNA), serves an oncogenic role in various types of cancer. The aim of the present study was to investigate the effect of SUMO1P3 on glioma progression. The results demonstrated that SUMO1P3 expression was upregulated in glioma tissues and cell lines. Furthermore, SUMO1P3 was associated with a poor overall survival of patients with glioma. The results of the in vitro cell proliferation and flow cytometry assays demonstrated that SUMO1P3‑knockdown suppressed cell proliferation and cell cycle. The results of the wound healing and Transwell assays demonstrated that SUMO1P3‑knockdown significantly repressed cell migration and invasion. In addition, SUMO1P3 promoted glioma by regulating the expression levels of β‑catenin, cyclin‑D1, N‑cadherin and E‑cadherin. Overall, the results of the present study suggested that SUMO1P3 may act as an oncogene by regulating cell proliferation, cell cycle, cell migration and invasion in glioma, and may represent a novel diagnostic biomarker and therapeutic target for glioma.

View Figures

View References

1	Siegel RL, Millaer KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI View Article : Google Scholar
2	Bielle F: Building diagnoses with four layers: WHO 2016 classification of CNS tumors. Rev Neurol (Paris). 172:253–255. 2016.PubMed/NCBI View Article : Google Scholar
3	Boussiotis VA and Charest A: Immunotherapies for malignant glioma. Oncogene. 37:1121–1141. 2018.PubMed/NCBI View Article : Google Scholar
4	Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: The avenue to a cure for malignant glioma. CA Cancer J Clin. 60:166–193. 2010.PubMed/NCBI View Article : Google Scholar
5	Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, et al: Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA. 318:2306–2316. 2017.PubMed/NCBI View Article : Google Scholar
6	Bhan A, Soleimani M and Mandal SS: Long noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981. 2017.PubMed/NCBI View Article : Google Scholar
7	Wang JZ, Xu CL, Wu H and Shen SJ: LncRNA SNHG12 promotes cell growth and inhibits cell apoptosis in colorectal cancer cells. Braz J Med Biol Res. 50(e6079)2017.PubMed/NCBI View Article : Google Scholar
8	Wang O, Yang F, Liu Y, Lv L, Ma R, Chen C, Wang J, Tan Q, Cheng Y, Xia E, et al: C-MYC-induced upregulation of lncRNA SNHG12 regulates cell proliferation, apoptosis and migration in triple-negative breast cancer. Am J Transl Res. 9:533–545. 2017.PubMed/NCBI
9	Wang P, Chen D, Ma H and Li Y: LncRNA SNHG12 contributes to multidrug resistance through activating the MAPK/Slug pathway by sponging miR-181a in non-small cell lung cancer. Oncotarget. 8:84086–84101. 2017.PubMed/NCBI View Article : Google Scholar
10	Zhang H and Lu W: LncRNA SNHG12 regulates gastric cancer progression by acting as a molecular sponge of miR320. Mol Med Rep. 17:2743–2749. 2018.PubMed/NCBI View Article : Google Scholar
11	Gordon MA, Babbs B, Cochrane DR, Bitler BG and Richer JK: The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. Mol Carcinog. 58:196–205. 2019.PubMed/NCBI View Article : Google Scholar
12	Xu Y, Zhang X, Hu X, Zhou W, Zhang P, Zhang J, Yang S and Liu Y: The effects of lncRNA MALAT1 on proliferation, invasion and migration in colorectal cancer through regulating SOX9. Mol Med. 24(52)2018.PubMed/NCBI View Article : Google Scholar
13	Ye Y, Zhang F, Chen Q, Huang Z and Li M: LncRNA MALAT1 modified progression of clear cell kidney carcinoma (KIRC) by regulation of miR-194-5p/ACVR2B signaling. Mol Carcinog. 58:279–292. 2019.PubMed/NCBI View Article : Google Scholar
14	Jia L, Tian Y, Chen Y and Zhang G: The silencing of LncRNA-H19 decreases chemoresistance of human glioma cells to temozolomide by suppressing epithelial-mesenchymal transition via the Wnt/β-Catenin pathway. Onco Targets Therapy. 11:313–321. 2018.PubMed/NCBI View Article : Google Scholar
15	Cheng Z, Li Z, Ma K, Li X, Tian N, Duan J, Xiao X and Wang Y: Long non-coding RNA XIST promotes glioma tumorigenicity and angiogenesis by acting as a molecular sponge of miR-429. J Cancer. 8:4106–4116. 2017.PubMed/NCBI View Article : Google Scholar
16	Zhang R, Jin H and Lou F: The long non-coding RNA TP73-AS1 interacted with miR-142 to modulate brain glioma growth through HMGB1/RAGE pathway. J Cell Biochem. 119:3007–3016. 2018.PubMed/NCBI View Article : Google Scholar
17	Zhan Y, Liu Y, Wang C, Lin J, Chen M, Chen X, Zhuang C, Liu L, Xu W, Zhou Q, et al: Increased expression of SUMO1P3 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer. Oncotarget. 7:16038–16048. 2016.PubMed/NCBI View Article : Google Scholar
18	Liu J, Song Z, Feng C, Lu Y, Zhou Y, Lin Y and Dong C: The long non-coding RNA SUMO1P3 facilitates breast cancer progression by negatively regulating miR-320a. Am J Transl Res. 9:5594–5602. 2017.PubMed/NCBI
19	Zhang LM, Wang P, Liu XM and Zhang YJ: LncRNA SUMO1P3 drives colon cancer growth, metastasis and angiogenesis. Am J Transl Res. 9:5461–5472. 2017.PubMed/NCBI
20	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 World Health Organization Classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016.PubMed/NCBI View Article : Google Scholar
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
22	Deng D, Luo K, Liu H, Nie X, Xue L, Wang R, Xu Y, Cui J, Shao N and Zhi F: p62 acts as an oncogene and is targeted by miR-124-3p in glioma. Cancer Cell Int. 19(280)2019.PubMed/NCBI View Article : Google Scholar
23	Deng D, Xue L, Shao N, Qu H, Wang Q, Wang S, Xia X, Yang Y and Zhi F: miR-137 acts as a tumor suppressor in astrocytoma by targeting RASGRF1. Tumour Biol. 37:3331–3340. 2016.PubMed/NCBI View Article : Google Scholar
24	Chattopadhyay S, Chaklader M and Law S: Aberrant Wnt signaling pathway in the hematopoietic stem/progenitor compartment in experimental leukemic animal. J Cell Commun Signal. 13:39–52. 2019.PubMed/NCBI View Article : Google Scholar
25	Sun Y, Zheng ZP, Li H, Zhang HQ and Ma FQ: ANRIL is associated with the survival rate of patients with colorectal cancer, and affects cell migration and invasion in vitro. Mol Med Rep. 14:1714–1720. 2016.PubMed/NCBI View Article : Google Scholar
26	Mei D, Song H, Wang K, Lou Y, Sun W, Liu Z, Ding X and Guo J: Up-regulation of SUMO1 pseudogene 3 (SUMO1P3) in gastric cancer and its clinical association. Med Oncol. 30(709)2013.PubMed/NCBI View Article : Google Scholar
27	Ge X, Cui H, Zhou Y, Yin D, Feng Y, Xin Q, Xu X, Liu W, Liu S and Zhang Q: miR-320a modulates cell growth and chemosensitivity via regulating ADAM10 in gastric cancer. Mol Med Rep. 16:9664–9670. 2017.PubMed/NCBI View Article : Google Scholar
28	Zhao W, Sun Q, Yu Z, Mao S, Jin Y, Li J, Jiang Z, Zhang Y, Chen M, Chen P, et al: MiR-320a-3p/ELF3 axis regulates cell metastasis and invasion in non-small cell lung cancer via PI3K/Akt pathway. Gene. 670:31–37. 2018.PubMed/NCBI View Article : Google Scholar
29	Zhao H, Dong T, Zhou H, Wang L, Huang A, Feng B, Quan Y, Jin R, Zhang W, Sun J, et al: miR-320a suppresses colorectal cancer progression by targeting Rac1. Carcinogenesis. 35:886–895. 2014.PubMed/NCBI View Article : Google Scholar
30	Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ, Lee KH, Yeh SD, Hong TM and Chen YL: MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis. 34:530–538. 2013.PubMed/NCBI View Article : Google Scholar
31	Wu S, Chen S, Lin N and Yang J: Long non-coding RNA SUMO1P3 promotes hepatocellular carcinoma progression through activating Wnt/β-catenin signalling pathway by targeting miR-320a. J Cell Mol Med. 24:3108–3116. 2020.PubMed/NCBI View Article : Google Scholar
32	Fu M, Wang C, Li Z, Sakamaki T and Pestell RG: Minireview: Cyclin D1: Normal and abnormal functions. Endocrinology. 145:5439–5447. 2004.PubMed/NCBI View Article : Google Scholar
33	Tam WL and Weinberg RA: The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 19:1438–1449. 2013.PubMed/NCBI View Article : Google Scholar
34	Noh MG, Oh SJ, Ahn EJ, Kim YJ, Jung TY, Jung S, Kim KK, Lee JH, Lee KH and Moon KS: Prognostic significance of E-cadherin and N-cadherin expression in Gliomas. BMC cancer. 17(583)2017.PubMed/NCBI View Article : Google Scholar
35	Lou JY, Luo J, Yang SC, Ding GF, Liao W, Zhou RX, Qiu CZ and Chen JM: Long non-coding RNA SUMO1P3 promotes glioma progression via the Wnt/β-catenin pathway. Eur Rev Med Pharmacol Sci. 24:9571–9580. 2020.PubMed/NCBI View Article : Google Scholar